SCHEDULE: Velan Capital Boosts Edesa Biotech Stake to 9.99%

Velan Capital and its affiliates have increased their beneficial ownership in Edesa Biotech, Inc. to 9.99% of outstanding common shares.

Summary

• Velan Capital Investment Management LP and its affiliates now beneficially own 834,700 common shares of Edesa Biotech, Inc., representing 9.99% of the outstanding shares.
• This percentage is based on 8,348,161 shares outstanding as of February 12, 2026, as reported in Edesa Biotech's Form 10-Q.
• The ownership includes shares directly held by Velan Master Fund LP (6.8%), Velan Horizon Fund LP (0.2%), and Velan Capital Opportunity Fund II LLC (3.0%).
• If not for an Ownership Limitation on Preferred Shares, the Reporting Persons would collectively own 3,785,833 shares, or approximately 33.5% of the outstanding shares.
• Recent open market purchases by Velan Master Fund LP include 100,000 shares at $1.5429 on February 26, 2026, and 40,000 shares at $2.1001 on February 27, 2026.
• Warrants previously held by the Reporting Persons expired worthless on December 23, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for Edesa Biotech, as a significant increase in an institutional investor's stake, especially with a potential for much higher ownership, often signals confidence in the company's future prospects despite the worthless warrants.

Positives

• Velan Capital and its affiliates have increased their aggregate beneficial ownership to 9.99%, signaling continued confidence in Edesa Biotech.
• The potential ownership, if not for the Ownership Limitation, would be a substantial 33.5%, indicating a strong underlying interest.

Negatives

• Warrants previously held by the Reporting Persons expired worthless on December 23, 2025, indicating a loss on that specific investment vehicle.

Risks

• The Ownership Limitation on Preferred Shares restricts the immediate conversion of a significant portion of potential beneficial ownership (2,958,333 shares), which could limit the Reporting Persons' influence or ability to fully realize their investment.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Edesa Biotech. However, the increased stake by Velan Capital suggests a long-term investment perspective from the reporting persons.

Industry Context

StockSavvy.ai notes that increased institutional ownership, particularly from active investors like Velan Capital, can often signal a belief in a biotech company's long-term potential, especially given the inherent risks and long development cycles in the sector. Such a significant stake, approaching 10%, could also precede calls for strategic changes or board representation, common in activist investor scenarios within the biotech space.

Comparison to Industry Standards

• A 9.99% stake by an institutional investor like Velan Capital is a substantial position, often considered a significant minority stake. For comparison, activist investors typically build stakes ranging from 5% to 20% to exert influence.
• The disclosure of a potential 33.5% ownership if not for conversion limitations suggests a much deeper conviction, potentially aligning with stakes seen in private equity or strategic partnerships rather than typical public market minority investments.
• In the biotech sector, such large stakes can be held by venture capital firms or strategic partners, often with board seats, to guide drug development or commercialization efforts.

Stakeholder Impact

• Shareholders: Increased institutional ownership could be seen as a positive signal, potentially leading to increased share price stability or upward pressure. The potential for activist engagement could also benefit shareholders if it leads to value-enhancing changes.
• Management: Edesa Biotech's management may face increased scrutiny or engagement from Velan Capital regarding strategic decisions and performance.

Next Steps

• The Reporting Persons may continue to engage with Edesa Biotech's management and board regarding strategic direction, operational improvements, or corporate governance.
• The Reporting Persons may seek to convert additional Preferred Shares into common shares, subject to the Ownership Limitation.

Key Dates

Recommendation

The increased stake by Velan Capital, an active investor, signals confidence in Edesa Biotech. However, the expiration of warrants worthless and the existing ownership limitation on preferred shares introduce elements of caution. While the increased ownership is a positive indicator, it is not a strong enough catalyst for an immediate 'buy' recommendation without further insight into Velan Capital's specific intentions or Edesa Biotech's operational performance. A 'hold' position allows investors to monitor how this increased stake translates into strategic actions or improved company performance.

Keywords

Edesa Biotech, Velan Capital, Schedule 13D, Beneficial Ownership, Common Shares, Biotech Investment, Institutional Investor, Shareholder Activism, Equity Stake